ICE Regimen for Relapsed/Refractory Bone and Soft Tissue Sarcomas in Children


AYDIN G. B., AKYÜZ C., VARAN A., YALÇIN B., KURUCU N., Kutluk T.

REVIEWS ON RECENT CLINICAL TRIALS, cilt.13, sa.2, ss.126-131, 2018 (ESCI) identifier identifier identifier

Özet

Background: The outcome of bone and soft tissue sarcomas (BST) after relapse has very poor prognosis with survival rates less than 39%. Unfortunately there are not many treatment options, but promising responses have been reported with ifosfamide, etoposide and carboplatin (ICE).